Breaking News

ProBioGen’s GlymaxX Technology Reaches Phase III Development

Zymeworks recently announced a global Phase III clinical trial of zanidatamab in HER2‑expressing gastroesophageal cancer.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ProBioGen AG, a technology developer and CDMO for cell line development through GMP manufacturing, announced an important clinical milestone for its GlymaxX antibody-dependent cellular cytotoxicity (ADCC) enhancement technology. With Zymeworks’ recently announced global Phase III clinical trial of zanidatamab in HER2‑expressing gastroesophageal adenocarcinoma, the GlymaxX technology also reaches Phase III clinical development.   ProBioGen completed cell line development for Zanidatamab i...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters